BWX Technologies is drawing institutional capital from multiple directions. NFJ Investment Group has opened a new $39.27 million position in BWXT stock, Ceredex Value Advisors has invested $22.05 million, and Silvant Capital Management has acquired new shares. Three separate transactions, all targeting the same name, within a short timeframe. The signal is clear: professional asset managers are taking a concrete interest in American nuclear.
The investment case rests on solid fundamentals. BWX Technologies closed 2025 with a total funded backlog of $7.3 billion, up 119% year-over-year compared to the third quarter. The stock delivered a 56.4% return to shareholders over the year, and has gained nearly 90% over the past twelve months. The numbers speak for themselves. The company is North America’s leading manufacturer of specialized nuclear components, naval propulsion systems, and fuel for the U.S. Navy — a sole-source supplier that would be extremely difficult to replicate in the near term.
The commercial segment is the fastest-growing division. Commercial operations revenue climbed from $524 million in 2024 to $853 million in 2025, a 63% increase. In Q1 2026, the segment posted a further 121% jump to $284 million. Demand is coming from utilities extending the life of existing reactors, new small modular reactor projects, and customers in the medical isotopes sector. In April 2026, BWXT acquired Precision Components Group to build dedicated U.S. manufacturing capacity for next-generation commercial reactors — an early move into a market the company intends to dominate before demand reaches full maturity.
On the SMR front, the broader environment is favorable. The global small modular reactor market was valued at $5.96 billion in 2025 and is projected to reach $8.77 billion by 2034. BWXT is active in this space across both defense and civilian applications, positioning itself as a components and technology supplier rather than a pure-play developer. Its Cambridge, Ontario facility has been expanded to increase large nuclear component production capacity by 50%. The commercial segment backlog stood at $1.72 billion as of March 2026. Analysts forecast earnings per share growth of 15% in 2026 and 14% in 2027, with revenues expected to rise at a mid-to-high double-digit rate.
The convergence of institutional capital flows toward BWXT reflects a precise read of the market: while next-generation nuclear is still in the development phase, those supplying components, fuel, and engineering services to both existing and under-construction reactors are generating cash today. The interest from funds like NFJ and Ceredex is not speculative — it is a structural positioning play on an industry returning to growth after decades of stagnation. If electricity demand driven by data centers and artificial intelligence continues to accelerate, pressure on governments to expand nuclear capacity will grow in lockstep. And the companies manufacturing the physical components of those reactors will be very hard to replace.
